Breaking News Instant updates and real-time market news.

AKBA

Akebia

$13.62

0.56 (4.29%)

16:31
08/08/17
08/08
16:31
08/08/17
16:31

Akebia reports Q2 EPS (53c), consensus (89c)

Reports Q2 revenue $28.5M, consensus $26.5M. CEO John Butler said, "Our agreement with Vifor Pharma establishes vadadustat as its exclusive HIF product for distribution to Fresenius Medical Care, the largest kidney dialysis provider in the U.S., following FDA approval. In addition, we initiated our Phase 2 FO2RWARD study in patients with renal anemia who are hyporesponsive to erythropoiesis-stimulating agents, and plan to start our Phase 3 TRILO2GY trial in the second half of the year to confirm previous positive results of vadadustat administered on a three-times-weekly basis. Topline data from both of these studies are expected by the end of 2018, followed by results from our global Phase 3 program for vadadustat. Substantial financial commitments from our collaborators, together with our existing cash, position Akebia well in advance of multiple value-creating events anticipated over the next 12-18 months, including filing an IND for AKB-5169, our HIF product candidate for inflammatory bowel disease, in the first half of next year."

AKBA Akebia
$13.62

0.56 (4.29%)

12/27/16
HCWC
12/27/16
NO CHANGE
Target $18
HCWC
Buy
Akebia deal with Otsuka tops expectations, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Akebia Therapeutics to $18 from $17 saying the company's collaboration with Otsuka Pharmaceutical exceeded his expectations. The analyst is surprised that the stock is up only 27% after four full trading days since the deal's announcement for a "modest" $86M gain in market cap. He notes that Akebia now has more than enough committed capital to fully fund the entire Phase 3 vadadustat development program. Arce keeps a Buy rating on Akebia.
03/07/17
UBSW
03/07/17
NO CHANGE
Target $12
UBSW
Buy
Akebia below fair value with readouts due in second half, says UBS
UBS analyst Jeffrey Hung noted Akebia provided an update to its development programs on their Q4 call and he believes the shares continue to trade below fair value. He acknowledged there is a lack of stock-moving catalysts at this time, but said the company is on track for data readouts in the second half of 2017. Hung reiterated his Buy rating and $12 price target on Akebia shares.
04/26/17
AGIS
04/26/17
NO CHANGE
Target $25
AGIS
Buy
Aegis says Akebia's expanded deal with Otsuka could lead to a takeout
Aegis analyst Difei Yang said Aekbia's expanded collaboration agreement with Otsuka for vadadustat is valued at $865M, comprising a $73M upfront fee, at least $135M in further development funding, and up to $657M in milestone payments. The analyst said the deal is positive for Akebia as it expands its collaboration with Otsuka and removes a financial overhang. Yang also sees the potential for Buy rated Akebia to be acquired by Otsuka after a positive Phase III readout and raised his price target on shares to $25 from $21.
05/16/17
NEED
05/16/17
NO CHANGE
Target $21
NEED
Buy
Akebia price target raised to $21 from $18 at Needham
Needham analyst Chad Messer raised his price target for Akebia Therapeutics to $21 after the company entered into a license agreement to sell vadadustat to Fresenius Medical Care dialysis clinics in the U.S. The deal is a positive for both the future commercial opportunity and the immediate funding needs at Akebia, Messer tells investors in a research note. He reiterates a Buy rating on the shares.

TODAY'S FREE FLY STORIES

NKE

Nike

$73.94

-0.785 (-1.05%)

07:37
06/22/18
06/22
07:37
06/22/18
07:37
Downgrade
Nike rating change  »

Nike downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

AYX

Alteryx

$38.63

-1.21 (-3.04%)

07:36
06/22/18
06/22
07:36
06/22/18
07:36
Initiation
Alteryx initiated  »

Alteryx initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALBO

Albireo Pharma

$36.05

1.05 (3.00%)

07:36
06/22/18
06/22
07:36
06/22/18
07:36
Conference/Events
Albireo Pharma management to meet with Needham »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

INTC

Intel

$52.19

-1.27 (-2.38%)

, JPM

JPMorgan

$107.52

-0.04 (-0.04%)

07:35
06/22/18
06/22
07:35
06/22/18
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

INTC

Intel

$52.19

-1.27 (-2.38%)

JPM

JPMorgan

$107.52

-0.04 (-0.04%)

MS

Morgan Stanley

$49.78

-0.095 (-0.19%)

PG

Procter & Gamble

$76.44

0.59 (0.78%)

LUV

Southwest

$53.15

1.16 (2.23%)

PAGS

PagSeguro Digital

$29.42

0.91 (3.19%)

COTY

Coty

$14.48

0.03 (0.21%)

HBI

Hanesbrands

$22.04

0.615 (2.87%)

SYK

Stryker

$169.81

0.21 (0.12%)

ECA

Encana

$12.19

-0.235 (-1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

  • 13

    Jul

  • 24

    Jul

  • 26

    Jul

  • 12

    Oct

  • 22

    Jun

SRPT

Sarepta

$149.57

-4.12 (-2.68%)

07:34
06/22/18
06/22
07:34
06/22/18
07:34
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBIO

iBio

$0.95

-0.12 (-11.22%)

07:33
06/22/18
06/22
07:33
06/22/18
07:33
Syndicate
iBio raises $16M in a public offering »

The securities offered by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMG

Chipotle

$462.87

-2.66 (-0.57%)

07:33
06/22/18
06/22
07:33
06/22/18
07:33
Periodicals
Chipotle will test new menu items, strategy, NY Times reports »

Chipotle is adding five…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 26

    Jul

ABBV

AbbVie

$95.55

-2.72 (-2.77%)

07:33
06/22/18
06/22
07:33
06/22/18
07:33
Recommendations
AbbVie analyst commentary  »

AbbVie most exposed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEA

Lear

$198.83

-2.565 (-1.27%)

07:32
06/22/18
06/22
07:32
06/22/18
07:32
Conference/Events
Lear to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

QCOM

Qualcomm

$58.76

-0.03 (-0.05%)

, NXPI

NXP Semiconductors

$112.55

-0.42 (-0.37%)

07:31
06/22/18
06/22
07:31
06/22/18
07:31
Hot Stocks
Qualcomm extends cash offer for NXP Semiconductors to June 29 »

Qualcomm (QCOM) announced…

QCOM

Qualcomm

$58.76

-0.03 (-0.05%)

NXPI

NXP Semiconductors

$112.55

-0.42 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 10

    Jul

  • 12

    Jul

FOXA

21st Century Fox

$48.34

0.24 (0.50%)

, RIG

Transocean

$11.94

-0.575 (-4.60%)

07:30
06/22/18
06/22
07:30
06/22/18
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

FOXA

21st Century Fox

$48.34

0.24 (0.50%)

RIG

Transocean

$11.94

-0.575 (-4.60%)

CSX

CSX

$64.06

-0.81 (-1.25%)

Z

Zillow

$61.83

-2.84 (-4.39%)

KMB

Kimberly-Clark

$100.15

-1.51 (-1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 26

    Aug

WSC

Williams Scotsman

$12.10

-0.3 (-2.42%)

07:30
06/22/18
06/22
07:30
06/22/18
07:30
Hot Stocks
Breaking Hot Stocks news story on Williams Scotsman »

WillScot Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SENS

Senseonics

$4.96

0.1 (2.06%)

07:29
06/22/18
06/22
07:29
06/22/18
07:29
Recommendations
Senseonics analyst commentary  »

Senseonics FDA approval…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

CAKE

Cheesecake Factory

$59.87

2.13 (3.69%)

07:28
06/22/18
06/22
07:28
06/22/18
07:28
Downgrade
Cheesecake Factory rating change  »

Cheesecake Factory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WSC

Williams Scotsman

$12.10

-0.3 (-2.42%)

07:26
06/22/18
06/22
07:26
06/22/18
07:26
Conference/Events
Williams Scotsman to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SLNO

Soleno Therapeutics

$2.34

-0.02 (-0.85%)

07:26
06/22/18
06/22
07:26
06/22/18
07:26
Initiation
Soleno Therapeutics initiated  »

Soleno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTD

Trade Desk

$91.53

-1.84 (-1.97%)

07:26
06/22/18
06/22
07:26
06/22/18
07:26
Recommendations
Trade Desk analyst commentary  »

Trade Desk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRTX

Heron Therapeutics

$40.00

9.3 (30.29%)

07:25
06/22/18
06/22
07:25
06/22/18
07:25
Recommendations
Heron Therapeutics analyst commentary  »

Heron Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

KLAC

KLA-Tencor

$110.31

0.54 (0.49%)

07:24
06/22/18
06/22
07:24
06/22/18
07:24
Downgrade
KLA-Tencor rating change  »

KLA-Tencor downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHT

Red Hat

$165.62

-3.64 (-2.15%)

07:24
06/22/18
06/22
07:24
06/22/18
07:24
Recommendations
Red Hat analyst commentary  »

Red Hat price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

CSCO

Cisco

$43.17

-0.58 (-1.33%)

07:24
06/22/18
06/22
07:24
06/22/18
07:24
Recommendations
Cisco analyst commentary  »

Cisco selloff brings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 12

    Jul

TNDM

TNDM

, DXCM

DexCom

$99.72

-0.88 (-0.87%)

07:23
06/22/18
06/22
07:23
06/22/18
07:23
Recommendations
TNDM, DexCom analyst commentary  »

Tandem Diabetes'…

TNDM

TNDM

DXCM

DexCom

$99.72

-0.88 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 25

    Jun

DRI

Darden

$107.07

13.8 (14.80%)

07:22
06/22/18
06/22
07:22
06/22/18
07:22
Recommendations
Darden analyst commentary  »

Darden price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 16

    Jul

  • 17

    Jul

VSLR

Vivint Solar

$5.00

-0.05 (-0.99%)

07:20
06/22/18
06/22
07:20
06/22/18
07:20
Upgrade
Vivint Solar rating change  »

Vivint Solar upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ES

Eversource

$55.70

-0.1 (-0.18%)

, CTWS

Connecticut Water

$66.53

0.28 (0.42%)

07:20
06/22/18
06/22
07:20
06/22/18
07:20
Upgrade
Eversource, Connecticut Water rating change  »

Eversource upgraded to…

ES

Eversource

$55.70

-0.1 (-0.18%)

CTWS

Connecticut Water

$66.53

0.28 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.